Board of Directors
Tim Wilson, PhD.
Chief Executive Officer
Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including
David Chiswell has more than 30 years’ experience in the biotechnology industry. He co-founded Cambridge Antibody Technology (CAT) in 1990 where he served as CEO for six years.
Dr. Marianne Uteng is a Principal at the Novartis Venture Fund in Basel, Switzerland. Prior to joining NVF, she worked in Novartis Global Drug Development and, before that,
Marianne is a Partner at 3B Future Health Ventures, advisor to a venture capital fund investing in early-stage companies developing novel technologies and new treatments in oncology and
Pete joined Epidarex Capital as a Venture Partner in 2014. He has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining
Alek Safarian is the CEO of venture investment firm, ALSA Holdings Ltd. Alek has a diverse background in drug development spanning some 30 years. Trained as a pharmacist,
Emma is a Senior Investment Manager in the British Patient Capital Direct Investments team, where she focuses on opportunities in the life sciences. Emma joined the BPC team